Announcements Trials

Browse Landscape

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 9 Stomach Neoplasms 6 Neoplasm Metastasis 4 Carcinoma, Non-Small-Cell Lung 4 Carcinoma, Hepatocellular 4 Solid Tumor 3 Neoplasms 3 Breast Neoplasms 3 Triple Negative Breast Neoplasms 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Extranodal NK-T-Cell 2 Lung Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Carcinoma, Transitional Cell 2 Advanced Solid Tumors 2 Advanced Solid Tumor 2 Urologic Neoplasms 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Urinary Bladder Diseases 1 Thyroid Carcinoma, Anaplastic 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Small Cell Lung Cancer Extensive Stage 1 Sarcoma 1 Recurrence 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Muscle Invasive Bladder Cancer 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Muscle Invasive Bladder Cancer × tislelizumab × Clear all

NCT04813107 2022-02-22

ANTICIPATE

Jiangsu Yahong Meditech Co., Ltd aka Asieris

Phase 1/2 Unknown

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡